1. Home
  2. SPRO vs CLAR Comparison

SPRO vs CLAR Comparison

Compare SPRO & CLAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.24

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo Clarus Corporation

CLAR

Clarus Corporation

HOLD

Current Price

$2.64

Market Cap

103.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
CLAR
Founded
2013
1957
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Recreational Games/Products/Toys
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
103.7M
IPO Year
2017
1998

Fundamental Metrics

Financial Performance
Metric
SPRO
CLAR
Price
$2.24
$2.64
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$4.81
AVG Volume (30 Days)
261.3K
233.5K
Earning Date
03-26-2026
03-05-2026
Dividend Yield
N/A
3.75%
EPS Growth
111.81
11.68
EPS
0.15
N/A
Revenue
$66,802,000.00
$228,000.00
Revenue This Year
N/A
$5.27
Revenue Next Year
N/A
$4.56
P/E Ratio
$15.53
N/A
Revenue Growth
39.24
N/A
52 Week Low
$0.51
$2.59
52 Week High
$3.09
$4.03

Technical Indicators

Market Signals
Indicator
SPRO
CLAR
Relative Strength Index (RSI) 39.83 30.56
Support Level $2.15 $2.59
Resistance Level $2.44 $3.72
Average True Range (ATR) 0.13 0.11
MACD -0.02 0.01
Stochastic Oscillator 4.35 11.22

Price Performance

Historical Comparison
SPRO
CLAR

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About CLAR Clarus Corporation

Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.

Share on Social Networks: